Moderna and Merck announced their personalized mRNA cancer vaccine, Intismeran, reduced melanoma recurrence and spread in a late-stage trial, a first for mRNA cancer vaccines. The treatment, combined with Keytruda, targets tumor-specific mutations. Experts hope it will work against other cancers, with more trial results expected in coming years.
Moderna, Merck Cancer Vaccine Cuts Melanoma Recurrence
Source: Reuters